Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
FEBU
4776
AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF
FEBU
$52.1M
| $20.2K | ﹤0.01% |
728
-5,991
| -89% | -$165K |
2025 Q2
2 quarters
|
|
4777
Oramed Pharmaceuticals
ORMP
$187M
| $19.7K | ﹤0.01% |
6,917
-6,281
| -48% | -$16.2K |
2015 Q4
40 quarters
|
|
4778
CALL
FTAI Aviation
FTAI
$17.2B
| $19.7K | ﹤0.01% |
+100
| New | +$17K |
2025 Q4
0 quarters
|
|
4779
Invesco WilderHill Clean Energy ETF
PBW
$344M
| $19.7K | ﹤0.01% |
644
-126
| -16% | -$4.01K |
2021 Q1
19 quarters
|
|
4780
Star Group
SGU
$423M
| $19.2K | ﹤0.01% |
+1,618
| New | +$19.1K |
2025 Q4
0 quarters
|
|
|
ALFUU
4781
Centurion Acquisition Corp Unit
ALFUU
| $19.1K | ﹤0.01% |
1,791
| – | – |
2024 Q4
4 quarters
|
|
4782
ProShares UltraPro Short QQQ
SQQQ
$2.12B
| $18.9K | ﹤0.01% |
276
-15,780
| -98% | -$1.12M |
2025 Q2
2 quarters
|
|
4783
Afya
AFYA
$1.08B
| $18.5K | ﹤0.01% |
1,203
-2,130
| -64% | -$31.4K |
2025 Q3
1 quarter
|
|
4784
Vor Biopharma
VOR
$1.11B
| $18.3K | ﹤0.01% |
+1,399
| New | +$26.1K |
2025 Q4
0 quarters
|
|
|
EH
4785
EHang Holdings
EH
$314M
| $18.2K | ﹤0.01% |
1,383
-43,701
| -97% | -$690K |
2024 Q4
4 quarters
|
|
|
DDFL
4786
Innovator Equity Dual Directional 15 Buffer ETF - July
DDFL
$154M
| $18.2K | ﹤0.01% |
+886
| New | +$18K |
2025 Q4
0 quarters
|
|
|
DCBO
4787
Docebo
DCBO
$582M
| $18K | ﹤0.01% |
811
+100
| +14% | +$2.39K |
2024 Q3
5 quarters
|
|
4788
KB Financial Group
KB
$43.5B
| $18K | ﹤0.01% |
209
-181
| -46% | -$15.3K |
2022 Q2
14 quarters
|
|
|
GME.WS
4789
PUT
GameStop Corp Warrants
GME.WS
| $17.6K | ﹤0.01% |
+5,860
| New | +$18.2K |
2025 Q4
0 quarters
|
|
|
EMPG
4790
DELISTED
Empro Group
EMPG
| $17.2K | ﹤0.01% |
988
| – | – |
2025 Q3
1 quarter
|
|
4791
State Street SPDR Dow Jones International Real Estate ETF
RWX
$240M
| $16.8K | ﹤0.01% |
+600
| New | +$16.7K |
2025 Q4
0 quarters
|
|
4792
Innovator Uncapped Accelerated US Equity ETF
XUSP
$52.7M
| $16.8K | ﹤0.01% |
353
-3,075
| -90% | -$145K |
2025 Q1
3 quarters
|
|
4793
VanEck Agribusiness ETF
MOO
$1.17B
| $16.7K | ﹤0.01% |
+230
| New | +$16.7K |
2025 Q4
0 quarters
|
|
|
SAFX
4794
XCF Global Inc
SAFX
$137M
| $16.3K | ﹤0.01% |
59,750
+9,692
| +19% | +$7.54K |
2025 Q3
1 quarter
|
|
4795
FT Vest US Equity Buffer ETF October
FOCT
$1.21B
| $16.2K | ﹤0.01% |
331
-2,553
| -89% | -$123K |
2025 Q1
3 quarters
|
|
4796
Innovator US Equity Buffer ETF August
BAUG
$272M
| $16K | ﹤0.01% |
320
-196
| -38% | -$9.68K |
2024 Q4
4 quarters
|
|
|
DOCT
4797
FT Vest US Equity Deep Buffer ETF October
DOCT
$400M
| $15.9K | ﹤0.01% |
360
-511
| -59% | -$22.4K |
2024 Q3
5 quarters
|
|
4798
Skye Bioscience
SKYE
$7.44M
| $15.9K | ﹤0.01% |
+2,656
| New | +$31K |
2025 Q4
0 quarters
|
|
|
NVO
4799
CALL
Novo Nordisk
NVO
$165B
| $15.3K | ﹤0.01% |
300
-916,500
| -100% | -$46.9M |
2024 Q4
4 quarters
|
|
4800
FT Vest US Equity Buffer ETF February
FFEB
$1.43B
| $15.2K | ﹤0.01% |
269
-3,391
| -93% | -$189K |
2024 Q3
5 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.